
Sign up to save your podcasts
Or


Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug's potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
By JAMA Network4.3
106106 ratings
Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug's potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.

496 Listeners

162 Listeners

8,864 Listeners

112,194 Listeners

38 Listeners

21 Listeners

13 Listeners

11 Listeners

9 Listeners

16 Listeners

19 Listeners

5 Listeners

7 Listeners

29 Listeners

9 Listeners

93 Listeners

14 Listeners

5 Listeners

5 Listeners

369 Listeners

5,811 Listeners

18 Listeners

3 Listeners